Research programme: regenerative therapeutics - La Jolla PharmaceuticalAlternative Names: LJP-1485; Regenerative Immunophilin Ligands
Latest Information Update: 25 May 2012
At a glance
- Originator GliaMed
- Developer La Jolla Pharmaceutical Company
- Class Small molecules
- Mechanism of Action Immunophilin modulators
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Scars
Most Recent Events
- 30 Mar 2012 Discontinued - Preclinical for Scars in USA (unspecified route)
- 06 Apr 2011 Preclinical trials in Scars in USA (unspecified route)